GB Patent

GB2119248A — Insulin formulations and method of producing them

Assigned to Individual · Expires 1983-11-16 · 43y expired

What this patent protects

An insulin formulation comprises a solution of insulin in a dipolar aprotic solvent. A method of purifying insulin includes the steps of introducing a solution of impure insulin in a dipolar aprotic solvent into deionised water and removing the insulin precipitated therefrom. The…

USPTO Abstract

An insulin formulation comprises a solution of insulin in a dipolar aprotic solvent. A method of purifying insulin includes the steps of introducing a solution of impure insulin in a dipolar aprotic solvent into deionised water and removing the insulin precipitated therefrom. The solvents may be dimethyl sulphoxide, dimethyl sulpholane or 5,5-dimethyl-1,3-cyclohexanedione. The insulin formulations are stable and non-corrosive, and are especially suitable for use in implanted pump delivery systems for continuous insulin administration.

Drugs covered by this patent

Patent Metadata

Patent number
GB2119248A
Jurisdiction
GB
Classification
—
Expires
1983-11-16
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.